SPRAVATO®
A fast-acting, FDA-approved treatment for treatment-resistant depression that targets brain pathways involved in mood regulation to help improve symptoms and support recovery.
How SPRAVATO® can help you
SPRAVATO® offers a guided, evidence-based treatment pathway that can bring relief for some patients within the first few sessions. Unlike traditional daily antidepressants that primarily work over time, SPRAVATO® is designed to act on different brain pathways involved in mood and may help improve symptoms of depression, including in people who haven’t responded to other treatments. Over a structured treatment plan, it can support improved mood, functioning, and overall well-being, helping patients move toward feeling more like themselves again.
Is SPRAVATO® for you?
Your Symptoms
Treatment-resistant depression or PTSD
You have tried traditional medications and therapies without seeing meaningful results.
Burdened by daily medication
You’re tired of the daily pill cycle and looking for a safe, well-researched alternative to standard therapy.
Intense mood disorders or severe distress
You are dealing with overwhelming emotional drops, severe anxiety, or acute crisis thoughts.
How SPRAVATO® Helps
Rapid symptom relief
Some patients may experience improvement in depressive symptoms within the first few treatments, offering an early sense of relief.
Evidence-based care
An FDA-approved treatment for treatment-resistant depression, backed by extensive clinical research.
Sustained improvement over time
Supports longer-term improvement in symptoms through a different mechanism than traditional daily antidepressants.
A decline in your quality of life
Your mental health is actively getting in the way of your career, relationships, and daily routine.
Improved mood and function
Can help improve mood regulation and support better daily functioning and quality of life.
What to Expect on Your Journey
Step 1: The Consultation
Evaluation & History: A thorough clinical review with a qualified provider to ensure you are a safe candidate.
Tailored Planning: A collaborative discussion to map out your goals and give you clear preparation steps for your first session.
Step 2: The Treatment Phase
The Induction Series: A standard initial protocol of two infusion sessions per week for four weeks.
The Experience: Relax for approximately 1–2 hours in a quiet, deeply comfortable environment.
Step 3: Maintenance & Integration
Sustained Results: A personalized maintenance plan designed to lock in your long-term breakthrough.
Ongoing Support: Continued guidance from your care team to help you integrate your results into daily life.
Start your journey now.
Frequently Asked Questions
-
Ketamine is an anesthetic that has been used off-label for depression for years, typically administered via IV infusion.
Esketamine is a refined molecule derived from ketamine, it's the active component responsible for the antidepressant effect.
SPRAVATO® is the FDA-approved brand name esketamine nasal spray, manufactured by Janssen (Johnson & Johnson). Unlike IV ketamine, SPRAVATO® is FDA-cleared specifically for treatment-resistant depression and depressive symptoms in adults with suicidal ideation, and is covered by most major insurers.
-
SPRAVATO® is FDA-approved for two groups: adults with Treatment-Resistant Depression (TRD), meaning they haven't responded adequately to at least two antidepressants, and adults with Major Depressive Disorder who have active suicidal ideation with intent or behavior. It is always used alongside an oral antidepressant, not as a standalone treatment.
-
Treatment follows a structured schedule:
Induction (Weeks 1–4): Two sessions per week
Maintenance Phase 1 (Weeks 5–8): One session per week
Maintenance Phase 2 (Week 9 onward): One session every one to two weeks, based on your response.
Each appointment includes self-administering the nasal spray under clinical supervision, followed by a mandatory two-hour observation period before you can be cleared to leave.
-
The starting dose is 56mg. Based on your response and tolerability, your provider may increase it to 84mg. Your provider determines the right dose for you, it's not one-size-fits-all.
-
If SPRAVATO® doesn't provide sufficient relief or isn't a good fit, your provider will work with you on next steps. Other options may include TMS therapy, medication adjustments, or other interventions available at TSPC. You're never left without a path forward.
-
Yes, and you're required to. SPRAVATO® is only approved for use in combination with an oral antidepressant. Do not stop or change any medications without consulting your provider first.
-
No. SPRAVATO® is administered in a certified outpatient clinical setting, right here in our office. You self-administer the nasal spray under the supervision of our clinical staff, then rest in our observation area for two hours. You do not need to be hospitalized.
-
SPRAVATO® is FDA-approved for depression, not anxiety as a standalone diagnosis. However, many patients with depression also experience significant anxiety, and some report improvement in those symptoms as their depression lifts. Talk to your provider about your full symptom picture.
-
SPRAVATO® is covered by most major commercial insurers and Medicare when medical necessity criteria are met, typically documentation of treatment-resistant depression and failure of at least two antidepressants. Prior authorization is required. o ketamine or esketamine
Are pregnant or breastfeeding
Have uncontrolled hypertension
Have a history of psychosis or are currently experiencing psychotic symptoms-
Have active or unstable cardiovascular or cerebrovascular diseaseHave active or unstable cardiovascular or cerebrovascular disease
Your provider will conduct a full medical and psychiatric evaluation before starting treatment.